Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
GrantOptions (Right to Buy) · Derivative | 93,600 | Not disclosed Strike: $4.95 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 7 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
Disposition to issuerOptions (Right to Buy) · Derivative | 93,600 | Not disclosed Strike: $4.95 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 6 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,600 shares Expires 2027-02-17 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
GrantOptions (Right to Buy) · Derivative | 87,500 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 5 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
Disposition to issuerOptions (Right to Buy) · Derivative | 87,500 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 4 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2023-08-15 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
GrantOptions (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 3 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2020-12-31 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 22, 2017 Filed Jan 3, 2018 21:59 UTC |
BACHA JEFFREYDirector
|
Disposition to issuerOptions (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000905718-18-000015 · bacha_form4dec222017.xml · derivative · entry 2 BACHA JEFFREY · CIK 0001432149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2022-02-01 F2 · kind: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · price: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.exercise_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. F2 · derivative.expiration_date: Effective January 1, 2018, the Reporting Person's employment with the Issuer terminated. Pursuant to the terms of the Settlement Agreement dated December 22, 2017 between the Reporting Person and the Issuer, all of the Reporting Person's outstanding stock options became fully vested and exercisable on December 22, 2017, and terminate December 31, 2020. The Reporting Person shall continue to serve as a member of the board of directors. The six reported transactions in Table II disclose the deemed cancellation of "old" options and the grant of replacement options resulting from the foregoing amendments to the options. Read SEC document |
| December 13, 2017 Filed Jan 3, 2018 22:00 UTC |
Brown Dennis MDirector · Chief Scientific Officer
|
GiftCommon Stock | 129,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000016 · brown_form4dec132017.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,246 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his adult children, and an adult custodian of family members. This disposition was made for estate planning purposes. F1 · price: This transaction involved a gift of securities by the Reporting Person to his adult children, and an adult custodian of family members. This disposition was made for estate planning purposes. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 21:32 UTC |
Bell John KDirector
|
PurchaseCommon Stock | 18,129 | $0.81 | $14,684.49 |
DisclosureSEC source: 0001213900-17-012293 · f4111517bell_delmar.xml · nonDerivative · entry 2 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 95,019 F2 · price: This transaction was executed in multiple trades at prices ranging from $0.8086 to $0.81. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:32 UTC |
Bell John KDirector
|
PurchaseCommon Stock | 1,871 | $0.81 | $1,515.51 |
DisclosureSEC source: 0001213900-17-012293 · f4111517bell_delmar.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 76,890 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.7997 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 21:30 UTC |
Zarrabian SaiidDirector · Interim CEO
|
PurchaseCommon Stock | 5,900 | $0.84 | $4,956.00 |
DisclosureSEC source: 0001213900-17-012230 · f4111417zarrabian_delmar.xml · nonDerivative · entry 2 Zarrabian Saiid · CIK 0001495521 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Child Disclosed balance after: 5,900 F2 · price: This transaction was executed in multiple trades at prices ranging from $0.8298 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 21:30 UTC |
Zarrabian SaiidDirector · Interim CEO
|
PurchaseCommon Stock | 55,000 | $0.82 | $45,100.00 |
DisclosureSEC source: 0001213900-17-012230 · f4111417zarrabian_delmar.xml · nonDerivative · entry 1 Zarrabian Saiid · CIK 0001495521 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.8015 to $0.8385. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 03, 2017 Filed Nov 8, 2017 01:10 UTC |
Zarrabian SaiidDirector · Interim CEO
|
GrantOptions (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001213900-17-011531 · f4110317zarrabian_delmar.xml · derivative · entry 1 Zarrabian Saiid · CIK 0001495521 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-11-03 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 12:10 UTC |
BACHA JEFFREYDirector · CEO
|
PurchaseCommon Stock | 2,450 | $0.88 | $2,156.00 |
DisclosureSEC source: 0001213900-17-010402 · f4100617bacha_delmarpharm.xml · nonDerivative · entry 2 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,697 Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 12:10 UTC |
BACHA JEFFREYDirector · CEO
|
PurchaseCommon Stock | 7,550 | $0.87 | $6,568.50 |
DisclosureSEC source: 0001213900-17-010402 · f4100617bacha_delmarpharm.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,247 Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 22:05 UTC |
Praill Anthony ScottChief Financial Officer
|
PurchaseCommon Stock | 17,500 | $0.85 | $14,910.00 |
DisclosureSEC source: 0001213900-17-010332 · f4100517praill_delmar.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,366 Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 19:52 UTC |
Cranston Lynda SarahDirector
|
OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-010210 · f4092917cranston_delmarpharm.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,486 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:55 UTC |
BACHA JEFFREYDirector · CEO
|
OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-010216 · f4092917bacha_delmarpharm.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,697 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:55 UTC |
Bell John KDirector
|
OtherCommon Stock | 282 | $3.20 | $902.40 |
DisclosureSEC source: 0001213900-17-010214 · f4092917bell_delmarpharm.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 75,019 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:54 UTC |
Brown Dennis MDirector · Chief Scientific Officer
|
OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-010212 · f4092917brown_delmarpharm.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 885,346 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,846 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:51 UTC |
Mohr ErichDirector
|
OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-010208 · f4092917mohr_delmarpharm.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,166 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:50 UTC |
Praill Anthony ScottChief Financial Officer
|
OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-010206 · f4092917praill_delmarpharm.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,866 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:48 UTC |
TOTH ROBERT JOSEPH JRDirector
|
OtherCommon Stock | 74 | $3.20 | $236.80 |
DisclosureSEC source: 0001213900-17-010204 · f4092917toth_delmarpharm.xml · nonDerivative · entry 1 TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,295 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 01:02 UTC |
Bell John KDirector
|
ConversionExchangeable Shares · Derivative | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0001213900-17-008160 · f4080117bell_delmar.xml · derivative · entry 2 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. F1 · derivative.exercise_date: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. F1 · derivative.expiration_date: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 01:02 UTC |
Bell John KDirector
|
ConversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-008160 · f4080117bell_delmar.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 21:34 UTC |
Cranston Lynda SarahDirector
|
GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007476 · f4070717cranston_delmarpharm.xml · derivative · entry 2 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 21:34 UTC |
Cranston Lynda SarahDirector
|
GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007476 · f4070717cranston_delmarpharm.xml · derivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:41 UTC |
Zarrabian SaiidDirector
|
GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-17-000668 · zarrabian_form4jul72017.xml · derivative · entry 2 Zarrabian Saiid · CIK 0001495521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:41 UTC |
Zarrabian SaiidDirector
|
GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000905718-17-000668 · zarrabian_form4jul72017.xml · derivative · entry 1 Zarrabian Saiid · CIK 0001495521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:37 UTC |
TOTH ROBERT JOSEPH JRDirector
|
GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007480 · f4070717toth_delmarpharma.xml · derivative · entry 2 TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:37 UTC |
TOTH ROBERT JOSEPH JRDirector
|
GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007480 · f4070717toth_delmarpharma.xml · derivative · entry 1 TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:35 UTC |
Mohr ErichDirector
|
GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007478 · f4070717mohr_delmarpharma.xml · derivative · entry 2 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:35 UTC |
Mohr ErichDirector
|
GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007478 · f4070717mohr_delmarpharma.xml · derivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:33 UTC |
Bell John KDirector
|
GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007474 · f4070717bell_delmarpharma.xml · derivative · entry 2 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| July 07, 2017 Filed Jul 12, 2017 01:33 UTC |
Bell John KDirector
|
GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001213900-17-007474 · f4070717bell_delmarpharma.xml · derivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-07-07 F1 · derivative.exercise_date: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 14:27 UTC |
Cranston Lynda SarahDirector
|
OtherCommon Stock | 71 | $3.20 | $227.20 |
DisclosureSEC source: 0001213900-17-007145 · f4063017cranston_delmar.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,415 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:31 UTC |
TOTH ROBERT JOSEPH JRDirector
|
OtherCommon Stock | 74 | $3.20 | $236.80 |
DisclosureSEC source: 0001213900-17-007151 · f4063017toth_delmarpharma.xml · nonDerivative · entry 1 TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,221 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:30 UTC |
Praill Anthony ScottChief Financial Officer
|
OtherCommon Stock | 211 | $3.20 | $675.20 |
DisclosureSEC source: 0001213900-17-007149 · f4063017praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,655 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:29 UTC |
Mohr ErichDirector
|
OtherCommon Stock | 528 | $3.20 | $1,689.60 |
DisclosureSEC source: 0001213900-17-007147 · f4063017mohr_delmarpharma.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,638 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:25 UTC |
Brown Dennis MDirector · Chief Scientific Officer
|
OtherCommon Stock | 169 | $3.20 | $540.80 |
DisclosureSEC source: 0001213900-17-007143 · f4063017brown_delmarpharma.xml · nonDerivative · entry 1 Brown Dennis M · CIK 0001569520 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 885,177 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Includes 347,677 shares of the Issuer's common stock owned directly by reporting person and 537,500 shares of the Issuer's common stock held by Valent Technologies LLC, of which Reporting Person is the sole member and owner and holds sole voting and dispositive power over its shares. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:24 UTC |
Bell John KDirector
|
OtherCommon Stock | 282 | $3.20 | $902.40 |
DisclosureSEC source: 0001213900-17-007141 · f4063017bell_delmarpharma.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 49,737 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F2 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:23 UTC |
BACHA JEFFREYDirector · CEO
|
OtherCommon Stock | 176 | $3.20 | $563.20 |
DisclosureSEC source: 0001213900-17-007139 · f4063017bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,521 F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. F1 · price: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 11:31 UTC |
Cranston Lynda SarahDirector
|
PurchaseCommon Stock | 2,083 | $3.60 | $7,498.80 |
DisclosureSEC source: 0001213900-17-006882 · f4062617cranston_delmarpha.xml · nonDerivative · entry 1 Cranston Lynda Sarah · CIK 0001633660 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 2,344 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $10,000. Reported price is based on exchange rate of 0.75. F2 · ownership.nature: Shares are held by J.G. Cranston & Associates, Inc. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:34 UTC |
Praill Anthony ScottChief Financial Officer
|
PurchaseCommon Stock | 4,167 | $3.60 | $15,001.20 |
DisclosureSEC source: 0001213900-17-006886 · f4062617praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,444 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $20,000. Reported price is based on exchange rate of 0.75. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:33 UTC |
Mohr ErichDirector
|
PurchaseCommon Stock | 4,167 | $3.60 | $15,001.20 |
DisclosureSEC source: 0001213900-17-006884 · f4062617mohr_delmarpharma.xml · nonDerivative · entry 1 Mohr Erich · CIK 0001298170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,110 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $20,000. Reported price is based on exchange rate of 0.75. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:30 UTC |
Bell John KDirector
|
PurchaseCommon Stock | 4,167 | $3.60 | $15,001.20 |
DisclosureSEC source: 0001213900-17-006880 · f4062617bell_delmarpharma.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 49,455 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $20,000. Reported price is based on exchange rate of 0.75. F2 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 15:29 UTC |
BACHA JEFFREYDirector · CEO
|
PurchaseCommon Stock | 6,700 | $3.60 | $24,120.00 |
DisclosureSEC source: 0001213900-17-006878 · f4062617bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,345 F1 · price: The Reporting Person purchased the shares in a private transaction for an aggregate purchase price of CDN $32,160. Reported price is based on exchange rate of 0.75. Read SEC document |
| June 06, 2017 Filed Jun 6, 2017 21:23 UTC |
Praill Anthony ScottChief Financial Officer
|
PurchaseCommon Stock | 9,500 | $2.10 | $19,950.00 |
DisclosureSEC source: 0001213900-17-006200 · f4060617praill_delmarpharma.xml · nonDerivative · entry 1 Praill Scott · CIK 0001332948 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,277 Read SEC document |
| June 06, 2017 Filed Jun 6, 2017 21:12 UTC |
BACHA JEFFREYDirector · CEO
|
PurchaseCommon Stock | 5,000 | $2.12 | $10,600.00 |
DisclosureSEC source: 0001213900-17-006196 · f4060617bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,645 Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 15:46 UTC |
Bell John KDirector
|
PurchaseCommon Stock | 10,000 | $2.12 | $21,200.00 |
DisclosureSEC source: 0001213900-17-006217 · f4060617bell_delmarpharma.xml · nonDerivative · entry 1 Bell John K · CIK 0001569585 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Note Disclosed balance after: 45,288 F1 · ownership.nature: Shares are held by Onbelay Capital Inc. Read SEC document |
| May 05, 2017 Filed May 8, 2017 20:58 UTC |
BACHA JEFFREYDirector · Chief Executive Officer
|
PurchaseCommon Stock | 2,500 | $2.20 | $5,500.00 |
DisclosureSEC source: 0001213900-17-004749 · f4050517bacha_delmarpharma.xml · nonDerivative · entry 1 BACHA JEFFREY · CIK 0001432149 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,645 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.